4 min read

NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder

2 min read

Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting

1 min read

Cumulus Neuroscience to Present Data at Clinical Trials on Alzheimer’s Disease 2025 Annual Meeting

4 min read

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Annual Congress 2025